Business Context and Reporting Period
This Form 6-K filing by Icecure Medical Ltd. covers the period of January 2025, with a specific report date of January 13, 2025. The filing announces the execution of an Equity Distribution Agreement with Maxim Group LLC, enabling the company to offer and sell ordinary shares through an "at-the-market" offering program.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the terms of the new equity distribution agreement rather than reporting financial performance results.
Material Changes
The primary material change is the establishment of a new capital raising mechanism. On January 13, 2025, the company entered into an agreement allowing it to sell ordinary shares from time to time through Maxim Group LLC as the sales agent. This agreement is subject to the company's instructions regarding price, time, and size limits.
Guidance, Outlook, and Risks
- Agreement Terms: The company is not obligated to sell any shares under the agreement. The sales agent will use commercially reasonable efforts to sell shares based on company instructions.
- Compensation: The company will pay the sales agent a commission equal to 2.5% of the gross sales price per share sold.
- Expenses: The company has agreed to reimburse the sales agent for certain specified expenses.
- Legal and Regulatory: The offering is subject to applicable laws and Nasdaq Capital Market rules. The filing explicitly states it does not constitute an offer to sell in jurisdictions where such an offer would be unlawful.
Investor Verification Checklist
- Verify the full terms of the Equity Distribution Agreement attached as Exhibit 10.1.
- Review the company's current effective registration statement on Form F-3 (File No. 333-267272) referenced for the share offering.
- Monitor future transaction notices to determine the actual volume and pricing of shares sold under this program.
- Assess the impact of the 2.5% commission and reimbursement expenses on future capital raising efficiency.